Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415471 | 0.93 | PPARG (0.48) | CISD1PPARGCSNK2A2CLK1CSNK2B | |
| SCHEMBL1415438 | 0.91 | PPARG (0.49) | PPARGCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL1415512 | 0.91 | PPARG (0.48) | CISD1PPARGCSNK2A2CLK1CSNK2B | |
| SCHEMBL1415557 | 0.91 | CSNK2A2 (0.55) | PPARGCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL1415760 | 0.90 | PPARG (0.47) | CISD1PPARGCSNK2A2CLK1CSNK2B | |
| SCHEMBL1415475 | 0.90 | PPARG (0.47) | CISD1PPARGCSNK2A2CLK1CSNK2B | |
| SCHEMBL1415731 | 0.89 | PPARG (0.46) | CISD1PPARGCSNK2A2CLK1CSNK2B | |
| SCHEMBL1415773 | 0.89 | PPARG (0.46) | CISD1PPARGCSNK2A2CLK1CSNK2B | |
| SCHEMBL1415772 | 0.89 | PPARG (0.47) | PPARGCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL1415480 | 0.82 | SMN1; SMN2 (0.54) | CISD1KDM4EALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490360-B1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2011-03-16 | — | — | EP | claimed |
| EP-1490360-A4 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2006-07-05 | — | — | EP | claimed |
| EP-1490360-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2004-12-29 | — | — | EP | claimed |
| US-6787551-B2 | ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2004-09-07 | — | — | US | claimed |
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-06-24 | — | — | US | claimed |
| WO-2003080605-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2003-10-02 | — | — | WO | claimed |
| EP-1490360-B1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2011-03-16 | — | — | EP | disclosed |
| EP-1490360-A4 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2006-07-05 | — | — | EP | disclosed |
| EP-1490360-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2004-12-29 | — | — | EP | disclosed |
| US-6787551-B2 | ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2004-09-07 | — | — | US | disclosed |
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-06-24 | — | — | US | disclosed |
| WO-2003080605-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | GLP1R, PPARD, SLC5A1 | CISD1 453/4885PPARG 5/4885CSNK2A2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.